BCI
XENE icon

Brinker Capital Investments’s Xenon Pharmaceuticals XENE Stock Holding History

Brinker Capital Investments’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$852K Buy
14,114
+297
+2% +$16.5K 0.01% 1239
2026
Q1 		$803K Sell
13,817
-590
-4% -$27.2K 0.01% 1235
2025
Q4 		$646K Sell
14,407
-511
-3% -$21.5K ﹤0.01% 1478
2025
Q3 		$599K Buy
14,918
+2
+0% +$70 ﹤0.01% 1475
2025
Q2 		$467K Sell
14,916
-615
-4% -$20.1K ﹤0.01% 1532
2025
Q1 		$521K Buy
15,531
+2,095
+16% +$79.5K 0.01% 1406
2024
Q4 		$527K Sell
13,436
-1,067
-7% -$44.1K 0.01% 1333
2024
Q3 		$571K Sell
14,503
-11
-0.1% -$444 0.01% 1288
2024
Q2 		$566K Buy
14,514
+816
+6% +$32.6K 0.01% 1235
2024
Q1 		$590K Buy
13,698
+5,481
+67% +$252K 0.01% 1198
2023
Q4 		$393K Sell
8,217
-7,185
-47% -$254K ﹤0.01% 1301
2023
Q3 		$526K Sell
15,402
-404
-3% -$15.1K 0.01% 1187
2023
Q2 		$609K Buy
+15,806
New +$628K 0.01% 1148

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Brinker Capital Investments's XENE Position: Q2 2026 in Review

Brinker Capital Investments increased its Xenon Pharmaceuticals (XENE) stake by 2.1% in Q2 2026, buying an estimated $16.5K and bringing the position to 14,114 shares worth $852K. The position accounts for 0.01% of the portfolio, ranked #1239.

Brinker Capital Investments first reported a position in XENE in Q2 2023 and has held it in 13 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Brinker Capital Investments held 14,114 shares of Xenon Pharmaceuticals worth $852K as of Q2 2026.
  • Brinker Capital Investments bought 297 Xenon Pharmaceuticals shares in Q2 2026, an estimated $16.5K.
  • Xenon Pharmaceuticals made up 0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1239 holding.
  • Brinker Capital Investments first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.